Thank you, on Ioana. today. Good afternoon call everyone. We us appreciate you the joining
COVID-XX even this current obviously going able rate financials, related It's Really we're with progress, announcements each made been the us. of we address the time restrictions team's a our to to to addition In the high to a week. proud, very for of pandemic. three that maintain been busy the
follow of our to in, I say will team's any aware we're continue appropriate and we staff critical or measures before to to the our performance. safety of among maintain that Just and dive COVID-XX not consultants, want we cases
we're today's four going main to on cover call, So topics.
lead program OpRegen from for will our trial, data Dry we clinical the that's new First, announced AMD. review the I
which our explain option we oncology make forward. significantly will efforts exercise an the Research conducted why going I'll early of immune VAC prominent Second, U.K., with Cancer more
plans Third, questions. will vaccine I with after platform financials for we've spinal our we'll cell then provide made therapy about I'll an the Brandy will and VAC and review updates, on talk update open toward cord to to OPCX, injuries. fourth, developing recently up apply COVID-XX. our for progress the those finally, And our a line program address And
OpRegen with important only We sufferers, a please this our Wednesday. for continues data The at most to which Starting with FDA-approved no modest new with GA, asset therapies. OpRegen, this be but and ARVO competitors. of candidate product to present past clinical is our therefore, believe AMD OpRegen attractive the millions are Virtual we commercial Dry the were opportunity again of Meeting for number there for incredibly is
The presentation of the Director and Cincinnati was given Eye University Medicine. at by Dr. Fellowship and School of Christopher Riemann, Cincinnati Vitreoretinal Institute Surgeon
study. is one newly of sites Riemann's OpRegen clinic our in Dr. open the
system. the important brings as of perspective But he delivery our this So, as cell program. very the me, happens excuse surgeons Gyroscope has and retina first any be because Orbit presented engraftment, purity OpRegen is helped one cell the to to And relevant therapy data. is that just who time he because he -- delivery design a
can watch there website. on has his presentation XX-minute our presentation our posted website, been Riemann's Dr. to you so
population. better patients are those represent can you since I results the summary, patients our are just ones encouraging baseline more from legally intended into we is with blind what tell who And vision. want that closely If moving you seeing target
of and to-date, they of to better think to just treated patients cohort XX/XXX. XX assess atrophy, we've large XX/XXX also average that the them had average an for first we very the recent we smaller suited which with baseline areas whereas geographic atrophy, of respond and geographic So, They treated areas makes treatment vision patients that have have of an OpRegen.
consistent We three first to directional in separate improvements seen were that report time metrics. some pleased we patients across have for the
means improved of visual to slower three seeing and acuity, -- speed, untreated progression that patient. reading or So, and single seeing faster in changes the compared BCVA all those of eye GA a
evidence in These GA BCVA in cohort that five are patients cohort and for pooled the so differences are only progression also There data. far. in
certainly than more statistical these we evidence continue. have So, we're will trends hopefully significance, of trends but
The dose four our next error bars we as will tighten patients.
retina, we also anatomical changes have monitor which reduction to and continue and We seen report evidence in soft will to on. drusen of the
patient engraftment sustained years. of Evidence four to is in treated out our now earliest
about I think cells. worried the So, transplanted durability comfortably not are that of these say we we can
have experiences SDS We positive Orbit in with device our surgical combination formulation. also with two thaw-and-inject had Gyroscopes
once We conclude portion those from that study, but of if are formulation, four Orbit those do the study the dosed, we to the seen new conclude patients increasingly that are results X/Xa use Phase the would that device of the and we patients at patients confident results four to results in to Orbit the our comparable plan with in another are the want will to-date, and we've time. confirm
XXth, what is a going we to meantime, final and deeper X X available X. four analysts answer can that's discuss call P.M. and the be Cohort in AMD on patients next the questions identify like May you'd we Pacific doing to and Monday, P.M. Dr. Eastern. into If at to our dig In be will data data, Dry treat to the Riemann
is to next few activities trial completing I'm happy clinical surgery course elective has share informed and procedures the of to Dr. the plan over his weeks. Riemann that reinitiate that us their center
protect the and and OpRegen first be as They trial the eligible identified to to safety already are established standardized the will of have of personnel. soon one an treating patients begin site as patients procedures patient their
But positive able week. we I share things data think strategies. very that are partnership do to it want to help additional this was regulatory So, well. We clinical to a our were collect and overall, inform trending patient update
Moving we pluripotent marker established our next specific is dendritic booster cell vaccine. your dendritic load comprised acts to cancer This lines educating off-the-shelf and product T attack VAC, to tumor destroy out from back is cancer cell manufacture candidate this see for with cells a to of mature a to and immune like system body's your immune cells cells to and eliminate instruct cells the cancer by system. which
they lung charity Cancer Phase conducting to largest partner, is VAC development dedicated X been research. Our cell with a clinical have world's to U.K. trial Research cancer. or lives the U.K. CR saving And non-small through of cancer patients
year. original plan was U.K. that Asterias, the not treat here whether by that the initial partnership into acquired program that XX could Asterias, CR a upon at time of was require a to is and This entered now last based that decide in would Lineage, study or the the company patients data. we And phase
didn't to as early option exercise convincing was enough And of we for that feel happens, elected necessary be it were data to early. the we all patients to wait the the sometimes treated and
education to to next after already cells. And the a just concern T was that explain option that four to the back exercise dendritic may It clear early long patients. to this I not enroll over targeted to of was it take decision six us could do want provide how patients cells driven by
decision signal and option saw signal, We COVID positive both early exercise into multiple earlier we before VACX. clinical was pandemic in the data apparent which a the in autologous that assay so because we system, collected studies were And VACX hit. this to confirmed already leaning allogeneic
should driven I be. as a was to be data clear just obviously decision So want it that this
rolling immediately or coronavirus was wait that XX time knowing that, the sense was program for reacquire to of evidence to said that to it more not would having to the us restrictions, months even became likely six take clear this more it view. Now, additional change because and our that unlikely expected patients make than
there Additionally, to there needed of that with when lot back obtained a we like asset. that's development was OPCX on process is just
So begin our it further send to our group made on to CMC could immediately. that and work early regain it it control the program facility sense manufacturing so over
the of to assessment, to this the platform a be idea. us viral that glycoprotein. this And create a it could using determined were spike As by happening, all occurred further SARS-CoV-X the was coronavirus be of to novel vaccine antigen biology studying a we we adapted VAC after and like
this submitted patent provisional and we U.S. vaccines application a COVID of with discussing idea began So, U.K. CR
the that quickly That expanding strong of support the discussion on conducting All program happened and of COVID progressed begin I include speed impressive infectious disease immediately vaccine this for manufacturing and our this early scope so CR development, actually to to could options, work very from their initiative. really want rapidly U.K. simply credit immune-oncology of the team the both and exercise efforts.
data We ability from parties. five, in additional now to U.K. to current when to non-dilutive four for of back from CR well support CIRM. explore prophetically controlled So they're U.K. but agreed program. as has the to patients three, the disease only collecting and also we're VACX the I dose now, clinical also calling continue sites And the soon trial oncology infectious has buy as which applications, have seeking which not to patients applications X additional expect other permitted we're Lineage the
like about or thing COVID about that they same one these whether require a VACX talking programs and all development upfront. the that future of a I really this VACX, that There's vaccine, deal all is VACX, process work we're
really of an impact simultaneously. in spent on the dollar is investment all manufacturing of programs the cells So the the
Alameda lot final that's to And at the different advantage the lead facility. a of the our each our more defines only buck duplicated effort But we in for carries product expression the molecular individual which these taking of antigen, step all that specific manufacturing we've It's retained which to that get bang the the programs product. biologist lab internal effort. cassette by of
With space VAC for control to we're asset, position its bringing the the provide delivery could we a dendritic potential. access business as platform partnering the opportunities program companies in of explore tool. where reason in with full now to is cell immune-oncology in-house the Another development
product pipeline And much a is and oncology candidates combinations. we a various separate different platform. platform, cassettes, like types an with whole target very with of single-antigens either or expression could generate This of cancer
we discuss with that call area we're And that discussions. with enable us a a further will looking feel therapeutic hosting program. of exciting in product partnering this do into And to nature platform engage plans our expert the new and to
everyone share announcements. to help this today the rationale and to delighted really background the I'm understand So, behind
and will proceed be to do what out what clinic about transferring we forward. of we As we date, in the seen already Lineage, to information the we've more going CR program with plan U.K. sharing into and
funding. it's driver's a also and which clinical plan that we're the program, Overall, think vaccine, a tremendous seat oncology an oncology for for may back by in stage with disease platform amino a a be supported I positive non-dilutive Lineage broad infectious
program stage clinical our OPCX, for spinal to cord next Moving injury.
is team increase like working of production. and that the commercially manufacturing Our include control process production clinically which to up profile. some advantageous have consistency enabling been characteristics to working we cases product of in things to introduce scale and Attributes reproducibility and on better
And OPCX, OPCX some term next formulation thaw-and-inject accomplished formulation sites us more far thaw-and-inject duration of clinically the of enhancements a developing overall cost have enrolling as allow tested finish would we at and trial you clinical valuable thus program. development to conducted the as will A the and know, of benefits, reducing enable the successfully working sooner near to and with be on we're such OpRegen. for which
opportunities to runs, XX validate we OPCX, want scale production going those commercial the well made and Micro process dimensional differentiation The And your of process purity to into from the improve convert progress any dimensional as have has to is carriers production. as be approximately have to runs. of if have you they product, growth plates conducted team separate kind terrific micro several carriers, you on which three vessels. from on identified manufacturing enable two the essential
in massive production, and So there's volume increase scale. a
great RPE development work OPCX is advantages it's to affirmation get capabilities. And started yet we have who billion, the program. one out is key program really wanted and optimization the it's how these clear as folks possible. XX% And continuing, that that further think manufacturing pretty on made strides another early for cells back reason Process to pure of figured to cell therapy oligodendrocyte folks the I X underway our on that us but our manufacture that's
to with know injury new on connection in OPCX, spinal I that also let So wanted had delivery we've you for discussions evaluating device cord a now cells. further
exclusive an SDS out for has obtain option device decision far Our the AMD Gyroscope worked our well to really to program. thus
device ways exclusive a proprietary we're and delivery cord that So, looking copy we that at could spinal experience access and program. our for novel to gain
committed want is and combine Lineage before, of parts be said able interested to component I've total delivery, best the cells in as asset the to we're we Now, means available cannot to which piece by just proposition, long-term we not overall making management, cells to which seek think our an be treatment of and provide imitated. And help optimal ourselves care this for to that success. position is competition regimen going we outmaneuver every analyzing really production
So our for a for financials I’ll additional over updates review this to year. hand you can brief some now who plans Brandi, program there, and discuss things
